The 4 Wall Street analysts covering Hyperfine, Inc. hold a median 12-month price target of $2 — +178.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 31 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Hyperfine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (98): Sales and profits are climbing, and climbing faster than before.
Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on HYPR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +178.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Oct 2026 | Lucid Capital Markets | Initiates | Buy | $2.00 |
| 22 Sept 2026 | BTIG | Reiterates | Buy | $2.00 |
| 22 Sept 2026 | BTIG | Reiterates | Buy | — |
| 14 Sept 2026 | BTIG | Reiterates | Buy | $2.00 |
| 14 Sept 2026 | BTIG | Reiterates | Buy | — |
| 10 Aug 2026 | B. Riley Securities | Reiterates | Buy | — |
| 10 Aug 2026 | B. Riley Securities | Reiterates | Buy | $2.00 → $1.60 |
| 29 Apr 2026 | BTIG | Initiates | Buy | $2.00 |
| 29 Apr 2026 | BTIG | Initiates | Buy | — |
| 19 Mar 2026 | Lake Street | Maintains | Buy | — |
| 15 Aug 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 14 Aug 2025 | Lake Street | Maintains | Buy | — |
| 15 May 2025 | B. Riley Securities | Maintains | Buy | — |
| 14 May 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 24 Mar 2025 | Lake Street | Initiates | Buy | — |
| 20 Mar 2025 | B. Riley Securities | Maintains | Buy | — |
| 18 Mar 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 22 Mar 2024 | Wells Fargo | Maintains | Equal-Weight | — |
| 30 Nov 2023 | Jefferies | Initiates | Hold | — |
| 15 Aug 2023 | B. Riley Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
HYPR appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Hyperfine, Inc. returned −35.3% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 25% of US stocks
Cheaper than 42% of US stocks
Cheaper than 71% of US stocks
Higher than 84% of US stocks
Higher than 73% of US stocks
Higher than 63% of US stocks
Higher than 11% of US stocks
Higher than 2% of US stocks
Higher than 14% of US stocks
Higher than 11% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Hyperfine, Inc. has a market value of $76.1M and an enterprise value of $46.1M.
Revenue in the twelve months to 30 June 2026: $16.5M. The latest quarter grew 44.8% year on year.
Net income over the same four quarters: −$34.9M, a −210.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.38.
Free cash flow in the twelve months to 30 June 2026: −$27.5M.
Trailing P/E: −1.7×; forward P/E: −2.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Hyperfine, Inc. employs 102 people — $162K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Hyperfine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Hyperfine said CE mark and UKCA approvals support the international expansion of its Swoop system Model 2, and highlighted portable MRI in brain health awareness efforts.
Why it matters — The approvals support the Model 2 rollout beyond the United States, relevant to HYPR watchers tracking the company’s product expansion.
Hyperfine announced it will report third-quarter 2026 financial results on November 9, 2026. Management will host a conference call at 1:30 p.m. Pacific / 4:30 p.m. Eastern, with a live audio webcast and archived recording.
Why it matters — HYPR watchers can note the scheduled date and time for the company's third-quarter results and accompanying management call.
Hyperfine reported preliminary, unaudited third-quarter 2026 revenue of approximately $6.0 million, described as a record, and reaffirmed its full-year 2026 revenue outlook of approximately $20 million to $22 million.
Why it matters — The report gives HYPR watchers an update on preliminary quarterly revenue and the company’s reaffirmed full-year revenue outlook.
Hyperfine has appointed Roots Pharmaceutical as the exclusive distributor of its Swoop portable brain MRI system in the United Arab Emirates and Kuwait, expanding access to its technology across Gulf Cooperation Council healthcare markets.
Why it matters — A HYPR watcher would care because this exclusive distribution partnership broadens the company's international market reach for its portable brain MRI product in the Gulf region.
MedtechWOMEN named Maria Sainz, President and CEO of Hyperfine, Inc., the recipient of its 2026 Ferolyn Powell Leadership Award. Sainz was recognized alongside Starlight Cardiovascular's Beverly Tang, who received the organization's first-ever Rising Star Award, at the annual MedtechVISION Conference in Menlo Park, California.
Why it matters — This industry recognition highlights Hyperfine's CEO, potentially raising the company's profile and credibility within the medtech community.
The 4 Wall Street analysts covering Hyperfine, Inc. have a median 12-month price target of $2, with estimates ranging from $1.6 to $2.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Hyperfine, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Hyperfine, Inc. 47 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Hyperfine, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +178.5% from the last close, and Ticker Nerd's factor model ranks Hyperfine, Inc. 47 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Hyperfine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HYPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.6 to $2.5 over the next 12 months.
Hyperfine, Inc. returned -35.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Hyperfine, Inc. Class A Common Stock represents the equity of Hyperfine, Inc., a health technology and medical device company focused on portable magnetic resonance imaging.
The most recent item we track (Business Wire, 22 Oct 2026): "Hyperfine Advances International Swoop System Model 2 Rollout and Highlights the Role of Portable MRI in Brain Health Awareness". Hyperfine said CE mark and UKCA approvals support the international expansion of its Swoop system Model 2, and highlighted portable MRI in brain health awareness efforts.
Hyperfine, Inc. Class A Common Stock represents the equity of Hyperfine, Inc., a health technology and medical device company focused on portable magnetic resonance imaging. The company develops and commercializes the Swoop portable MR imaging system, which is designed to support brain imaging and clinical monitoring in settings where traditional MRI systems are less practical. Hyperfine also provides related support, maintenance, and technical services tied to its imaging products. Its offerings serve hospitals, intensive care units, stroke centers, and other medical facilities that use portable neuroimaging to help broaden access to diagnostic imaging. Based in Guilford, Connecticut, Hyperfine operates in the medical specialties segment of the health technology market, where it combines imaging hardware, software, and service capabilities around ultra-low-field MRI applications.
CEO Ms. Maria Degois-Sainz · 102 employees · United States · https://www.hyperfinemri.com
